Biotech investing is about more than providing capital. It is about identifying transformative science, building strong companies and helping innovation progress from scientific insight to meaningful patient impact.
Beacon Therapeutics, backed by Forbion since 2023, is approaching an important inflection point. Topline data from its pivotal VISTA trial of laru-zova are expected in Q3 2026. A positive result could move this one-time gene therapy closer to becoming the first approved treatment for X-linked retinitis pigmentosa, a severe inherited retinal disease with no approved treatment today.
With encouraging earlier-stage clinical evidence, an experienced leadership team, a world-class investor syndicate and a broader ocular pipeline, Beacon reflects the qualities Forbion seeks when building enduring biotechnology companies.
In this article, Dmitrij Hristodorov, PhD, General Partner at Forbion, examines the science behind laru-zova, the significance of the upcoming VISTA readout and how specialist investors can help advance breakthrough innovation across diseases and therapeutic modalities.